Free Trial

Rigel Pharmaceuticals (RIGL) Competitors

Rigel Pharmaceuticals logo
$37.96 +0.14 (+0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$38.00 +0.04 (+0.11%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RIGL vs. FOLD, BCRX, MNKD, CLDX, INVA, NVAX, DVAX, OPK, GERN, and ZBIO

Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), Geron (GERN), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

Rigel Pharmaceuticals vs. Its Competitors

Rigel Pharmaceuticals (NASDAQ:RIGL) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Rigel Pharmaceuticals currently has a consensus target price of $38.20, suggesting a potential upside of 0.63%. Amicus Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 100.25%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Amicus Therapeutics is more favorable than Rigel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Amicus Therapeutics
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

Rigel Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Rigel Pharmaceuticals has a net margin of 36.51% compared to Amicus Therapeutics' net margin of -6.67%. Rigel Pharmaceuticals' return on equity of 438.89% beat Amicus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals36.51% 438.89% 57.03%
Amicus Therapeutics -6.67%-5.07%-1.23%

Rigel Pharmaceuticals has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$179.28M3.80$17.49M$5.417.02
Amicus Therapeutics$528.29M4.66-$56.11M-$0.12-66.58

In the previous week, Amicus Therapeutics had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 11 mentions for Amicus Therapeutics and 8 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.28 beat Amicus Therapeutics' score of 1.28 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rigel Pharmaceuticals
5 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amicus Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 9.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats Amicus Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RIGL vs. The Competition

MetricRigel PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$678.39M$2.59B$5.86B$10.15B
Dividend YieldN/A56.52%5.68%4.59%
P/E Ratio7.0223.5374.5225.93
Price / Sales3.80698.04536.78122.58
Price / Cash35.06171.1637.5660.44
Price / Book199.795.3712.166.29
Net Income$17.49M$32.95M$3.28B$270.77M
7 Day Performance-8.18%1.31%0.98%3.36%
1 Month Performance9.97%8.31%7.20%6.41%
1 Year Performance193.13%0.29%63.06%28.26%

Rigel Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RIGL
Rigel Pharmaceuticals
2.0524 of 5 stars
$37.96
+0.4%
$38.20
+0.6%
+191.6%$678.39M$179.28M7.02160News Coverage
Positive News
Short Interest ↓
FOLD
Amicus Therapeutics
3.9687 of 5 stars
$7.98
-0.1%
$16.00
+100.5%
-28.8%$2.46B$528.29M-66.49480Positive News
BCRX
BioCryst Pharmaceuticals
4.2641 of 5 stars
$8.19
-1.0%
$16.70
+103.9%
+4.4%$1.74B$450.71M-45.50530Positive News
MNKD
MannKind
4.418 of 5 stars
$5.57
+0.5%
$10.71
+92.4%
-11.6%$1.70B$285.50M50.64400Positive News
Short Interest ↓
CLDX
Celldex Therapeutics
2.3847 of 5 stars
$23.40
+2.3%
$46.67
+99.4%
-39.5%$1.52B$7.02M-7.77150Positive News
INVA
Innoviva
4.8927 of 5 stars
$20.46
-0.1%
$42.75
+108.9%
+0.2%$1.29B$358.71M66.00100Positive News
Short Interest ↓
NVAX
Novavax
4.4801 of 5 stars
$7.73
-2.2%
$14.29
+84.8%
-32.6%$1.28B$682.16M3.391,990Positive News
DVAX
Dynavax Technologies
4.4612 of 5 stars
$9.70
-3.6%
$24.33
+150.9%
-10.7%$1.18B$316.27M-21.09350Positive News
OPK
OPKO Health
4.4898 of 5 stars
$1.42
+5.2%
$2.75
+93.7%
-8.3%$1.07B$713.10M-5.682,997
GERN
Geron
3.1384 of 5 stars
$1.37
-2.1%
$4.19
+205.7%
-69.9%$893.22M$76.99M-10.5470Positive News
ZBIO
Zenas BioPharma
0.976 of 5 stars
$21.51
+4.9%
$36.67
+70.5%
N/A$863.68M$5M0.00N/AHigh Trading Volume

Related Companies and Tools


This page (NASDAQ:RIGL) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners